Access cutting-edge necrotizing myopathy treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Pittsburgh location
Preparing your pre-screening questions…
Access necrotizing myopathy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related necrotizing myopathy treatment provided free
Check if you qualify for this necrotizing myopathy clinical trial in Pittsburgh, PA
No-Cost Study Care
Local to Pittsburgh
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a randomized, placebo-controlled, double blinded phase 2 exploratory clinical trial of intravenously administered pooled human immunoglobulin (IVIG) in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune mediated necrotizing myopathy (IMNM). Planned enrollment is 12 individuals with active anti-HMGCR IMNM meeting inclusion and exclusion criteria. Assuming 20% drop-out, the investigators anticipate 10 participants will complete all study assessments. Enrolled participants will be
Sponsor: University of Alabama at Birmingham
Yes, this clinical trial (NCT06599697) has an active research site in Pittsburgh, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for necrotizing myopathy treatment options in Pittsburgh, PA, this clinical trial (NCT06599697) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced necrotizing myopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.